Why the study?
Is hypokalaemia associated with atrial fibrillation occurrence in persons at risk of AF undergoing continuous monitoring?
Is hypokalaemia associated with atrial fibrillation occurrence in persons at risk of AF undergoing continuous monitoring?
Answers are grounded in this paper and cite their sources.
Transient hypokalaemia is associated with atrial fibrillation occurrence, though it is often accompanied by higher rates of hypertension and diuretic use, suggesting complex underlying mechanisms such as hyperaldosteronism.
This commentary refers to ‘Hypokalaemia and atrial fibrillation detected by implanted loop recorders’, by A. K. Hessellund et al., https://doi.org/10.1093/eurheartj/ehaf623 and the discussion piece ‘Potassium and aldosterone as determinants of new-onset atrial fibrillation’, by F. B. Rossi et al., https://doi.org/10.1093/eurheartj/ehag057. We thank Rossi et al. on the interest in our post hoc analysis regarding the day-to-day association between plasma potassium levels and atrial fibrillation occurrence1 in the randomized LOOP study.2 Plasma potassium plays a key role in myocardial electrophysiology. Hypokalaemia is known to prolong action potential and repolarization duration and myocardial excitability. Essentially, our work represents a data-driven, exploratory effort. Its principal strength lies in the combination of a large sample of repeated potassium measurements and a large real-world population of persons at risk of atrial fibrillation (AF) undergoing continuous monitoring. Concerns regarding uncertainty about potassium levels, e.g. due to haemolysis and laboratory inter-variability, are relevant. We argue that the sheer number of measurements (n = 12 136) obtained from publicly regulated Danish laboratories across different time points and clinical contexts attenuates the risk of systematic bias. Westernized diet and day-to-day variation in sodium intake, causing fluctuation in sodium/potassium exchange, is an important consideration. Long-term low potassium-to-sodium intake likely increases the risk of intermittent hypokalaemia, likely amplified in those prone to aldosterone dysregulation. Linz and Chaldoupi3 highlighted primary hyperaldosteronism as a potential link between hypokalaemia, hypertension, and AF. Hyperaldosteronism may indeed be underdiagnosed,4 and in our study, 89%–90% of participants without—vs 96% with—measured hypokalaemia had hypertension at baseline.1 However, hyperaldosteronism-associated hypokalaemia is unlikely the sole driver, as participants with hypokalaemia also received more diuretics ∼44%–45% vs ∼26%–30%. Whether this difference is due to more resistant hypertension, as seen in hyperaldosteronism, remains unknown. Importantly, hypokalaemia was mostly transient, as 1316/1331 (99%) measurements of hypokalaemia occurred in persons with normal potassium levels at other time points.
No takes yet. Share an insight, caveat, or question.
Svendsen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: